A review on recent advances in assays for DNMT1: a promising diagnostic biomarker for multiple human cancers

Analyst. 2024 Feb 12;149(4):1002-1021. doi: 10.1039/d3an01915b.

Abstract

The abnormal expression of human DNA methyltransferases (DNMTs) is closely related with the occurrence and development of a wide range of human cancers. DNA (cytosine-5)-methyltransferase-1 (DNMT1) is the most abundant human DNA methyltransferase and is mainly responsible for genomic DNA methylation patterns. Abnormal expression of DNMT1 has been found in many kinds of tumors, and DNMT1 has become a valuable target for the diagnosis and drug therapy of diseases. Nowadays, DNMT1 has been found to be involved in multiple cancers such as pancreatic cancer, breast cancer, bladder cancer, lung cancer, gastric cancer and other cancers. In order to achieve early diagnosis and for scientific research, various analytical methods have been developed for qualitative or quantitative detection of low-abundance DNMT1 in biological samples and human tumor cells. Herein, we provide a brief explication of the research progress of DNMT1 involved in various cancer types. In addition, this review focuses on the types, principles, and applications of DNMT1 detection methods, and discusses the challenges and potential future directions of DNMT1 detection.

Publication types

  • Review

MeSH terms

  • Biomarkers / metabolism
  • Breast Neoplasms* / genetics
  • DNA (Cytosine-5-)-Methyltransferase 1 / metabolism
  • DNA (Cytosine-5-)-Methyltransferases* / genetics
  • DNA (Cytosine-5-)-Methyltransferases* / metabolism
  • DNA / metabolism
  • DNA Methylation
  • Female
  • Humans

Substances

  • DNA (Cytosine-5-)-Methyltransferases
  • DNA (Cytosine-5-)-Methyltransferase 1
  • DNA
  • Biomarkers